Skip to main
LIVN
LIVN logo

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 31%
Hold 31%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova's financial performance has shown a positive trajectory, with an operating margin increase of 180 basis points year-over-year, driven by improved gross margins and strategic SG&A management. The company is forecasting mid-single-digit revenue growth of 6.7% for 2024, alongside strong expectations for its cardiopulmonary segment, anticipating organic growth of 7.0-8.0% in 2025 due to product launches and market share gains. Additionally, LivaNova is addressing capacity constraints in its oxygenator production, having improved capacity by 10% in 2024 and projecting further enhancements of 10-15% in 2025, which positions the company favorably for sustained growth.

Bears say

LivaNova has experienced a deceleration in revenue growth, particularly within its Neuromodulation segment, which rose only 1.0% to $137.6 million, significantly lower than the previous quarter's growth of 8.8%. Additionally, the company's Cardiopulmonary sales, while growing by 11.2% to $181.7 million, have also shown a decline from the 15.4% growth seen in the prior quarter, indicating underlying operational challenges. The company's bear case scenario forecasts a further slowdown in revenue growth to low-single digits, alongside anticipated operating margin contraction and earnings that may fall below consensus estimates, suggesting a challenging outlook for the firm.

Livanova (LIVN) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 13 analysts, Livanova (LIVN) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.